source
- Windward Bio targets $204M Nasdaq IPO to fund Chinese respiratory drug programWindward Bio, a biotech backed by Sanofi, announced plans to go public on Nasdaq with an offering of 10.3 million shares priced between $16 and $18 each. The company expects net proceeds of about $…
- AbbVie and BMS each secure FDA approval, but impact of their neuro‑drug acquisitions remains uncertainAbbVie and Bristol Myers Squibb have both received FDA clearance for new Parkinson's treatments, prompting a fresh look at the large neuro‑focused deals they completed last year. AbbVie bought Cere…